JNJ. Nemunaitis

J. Nemunaitis

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


J. Nemunaitis has a total of 25 co-authors. Here are the top co-authors by number of shared publications:

  • B.L. Kemp

    From US OncologyBaylor University Medical Center, and Columbia Medical City, Dallas; and Section of Thoracic Molecular Oncology, Departments of Diagnostic Imaging, Pathology, Thoracic/Head and Neck Medical Oncology, and Biomathematics, The University of Texas M.D. Anderson Cancer Center, and Introgen Therapeutics, Inc, Houston, TX

    1 shared publication
  • B.S. Glisson

    From US OncologyBaylor University Medical Center, and Columbia Medical City, Dallas; and Section of Thoracic Molecular Oncology, Departments of Diagnostic Imaging, Pathology, Thoracic/Head and Neck Medical Oncology, and Biomathematics, The University of Texas M.D. Anderson Cancer Center, and Introgen Therapeutics, Inc, Houston, TX

    1 shared publication
  • D. Connors

    From US OncologyBaylor University Medical Center, and Columbia Medical City, Dallas; and Section of Thoracic Molecular Oncology, Departments of Diagnostic Imaging, Pathology, Thoracic/Head and Neck Medical Oncology, and Biomathematics, The University of Texas M.D. Anderson Cancer Center, and Introgen Therapeutics, Inc, Houston, TX

    1 shared publication
  • D. Weill

    From US OncologyBaylor University Medical Center, and Columbia Medical City, Dallas; and Section of Thoracic Molecular Oncology, Departments of Diagnostic Imaging, Pathology, Thoracic/Head and Neck Medical Oncology, and Biomathematics, The University of Texas M.D. Anderson Cancer Center, and Introgen Therapeutics, Inc, Houston, TX

    1 shared publication
  • D.D. Lawrence

    From US OncologyBaylor University Medical Center, and Columbia Medical City, Dallas; and Section of Thoracic Molecular Oncology, Departments of Diagnostic Imaging, Pathology, Thoracic/Head and Neck Medical Oncology, and Biomathematics, The University of Texas M.D. Anderson Cancer Center, and Introgen Therapeutics, Inc, Houston, TX

    1 shared publication
  • D.M. Nguyen

    From US OncologyBaylor University Medical Center, and Columbia Medical City, Dallas; and Section of Thoracic Molecular Oncology, Departments of Diagnostic Imaging, Pathology, Thoracic/Head and Neck Medical Oncology, and Biomathematics, The University of Texas M.D. Anderson Cancer Center, and Introgen Therapeutics, Inc, Houston, TX

    1 shared publication

Latest Publications

  • Adenovirus-Mediated p53 Gene Transfer in Sequence With Cisplatin to Tumors of Patients With Non–Small-Cell Lung Cancer

    by J. Nemunaitis, S.G. Swisher, T. Timmons, D. Connors, M. Mack, L. Doerksen, D. Weill, J. Wait, D.D. Lawrence, B.L. Kemp, et al.

    PURPOSE: To determine the safety and tolerability of adenovirus-mediated p53 (Adp53) gene transfer in sequence with cisplatin when given by intratumor injection in patients with non–small-cell lung cancer (NSCLC). PATIENTS AND METHODS: Patients with advanced NSCLC and abnormal p53 function were enrolled onto cohorts receiving escalating dose levels of Adp53 (1 × 106 to 1 × 1011 plaque-forming units [PFU]). Patients were administered intravenous cisplatin 80 mg/m2 on day 1 and study vector on day 4 for a total of up to six courses (28 days per course). Apoptosis was determined by the terminal deoxynucleotidyl- transferase-dUTP nick–end labeling assay. Evidence of vector-specific sequences were determined using reverse-transcriptase polymerase chain reaction. Vector dissemination and biodistribution was monitored using a series of assays (cytopathic effects assay, Ad5 hexon enzyme-linked immunosorbent assay, vector-specific polymerase chain reaction assay, and antibody response assay). RESULTS: Twenty-four patients (median age, 64 years) received a total of 83 intratumor injections with Adp53. The maximum dose administered was 1 × 1011 PFU per dose. Transient fever related to Adp53 injection developed in eight of 24 patients. Seventeen patients achieved a best clinical response of stable disease, two patients achieved a partial response, four patients had progressive disease, and one patient was not assessable. A mean apoptotic index between baseline and follow-up measurements increased from 0.010 to 0.044 (P = .011). Intratumor transgene mRNA was identified in 43% of assessable patients. CONCLUSION: Intratumoral injection with Adp53 in combination with cisplatin is well tolerated, and there is evidence of clinical activity.